EP0306525A4 - Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus - Google Patents

Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus

Info

Publication number
EP0306525A4
EP0306525A4 EP19880903550 EP88903550A EP0306525A4 EP 0306525 A4 EP0306525 A4 EP 0306525A4 EP 19880903550 EP19880903550 EP 19880903550 EP 88903550 A EP88903550 A EP 88903550A EP 0306525 A4 EP0306525 A4 EP 0306525A4
Authority
EP
European Patent Office
Prior art keywords
diabetes mellitus
insulin sensitivity
reductase inhibitors
aldose reductase
enhance insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19880903550
Other versions
EP0306525A1 (en
Inventor
Billie M. York, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of EP0306525A1 publication Critical patent/EP0306525A1/en
Publication of EP0306525A4 publication Critical patent/EP0306525A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19880903550 1987-03-20 1988-03-18 Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus Withdrawn EP0306525A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2851287A 1987-03-20 1987-03-20
US28512 1987-03-20

Publications (2)

Publication Number Publication Date
EP0306525A1 EP0306525A1 (en) 1989-03-15
EP0306525A4 true EP0306525A4 (en) 1991-04-24

Family

ID=21843865

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880903550 Withdrawn EP0306525A4 (en) 1987-03-20 1988-03-18 Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus

Country Status (6)

Country Link
EP (1) EP0306525A4 (en)
JP (1) JPH01503460A (en)
KR (1) KR890700346A (en)
AU (1) AU598366B2 (en)
CA (1) CA1310269C (en)
WO (1) WO1988006887A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR100343944B1 (en) * 2001-02-14 2002-07-24 주식회사 에이.비.아이 Composition of L-2-oxothiazolidine-4-carboxylic acid or its saits as non-insulin dependent diabetes therapeutic agent

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4436745A (en) * 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) * 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147797A (en) * 1978-08-11 1979-04-03 Pfizer Inc. Spiro-furanohydantoin derivatives
US4251258A (en) * 1978-09-29 1981-02-17 Monsanto Company N-(Substituted carbonyl) derivatives of N-phosphinylmethylglycinates and the herbicidal use thereof
US4226875A (en) * 1979-04-02 1980-10-07 Pfizer Inc. Novel spiro-oxazolidinediones
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives
US4254108A (en) * 1979-11-08 1981-03-03 Ayerst, Mckenna & Harrison Inc. Thioxo-1H-benz[de]isoquinoline-2(3H)-acetic acid derivatives and antidiabetic use thereof
US4430337A (en) * 1982-06-23 1984-02-07 Pfizer Inc. Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
JPS6178725A (en) * 1984-09-20 1986-04-22 アメリカン・ホーム・プロダクツ・コーポレイシヨン Stabilized tolrestat rotation isomer composition
US4604406A (en) * 1984-11-16 1986-08-05 Ayerst, Mckenna & Harrison, Inc. N-[6-methoxy-5-(perfluoroalkyl)-1-naphtholyl]-N-methylglycines and their thionaphthoyl analogs
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4436745A (en) * 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) * 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Biochimica et Biophysica Acta, Vol. 870, 1986, pages 302-311, Elsevier Science Publishers B.V. (Biomedical Division); S.K. SRIVASTAVA et al.: "Hyperglycemia-induced activation of human erythrocyte aldose reductase and alterations in kinetic properties", Abstract. *
Chem. Pharm. Bull., Vol. 32, No. 5, 1984, pages 2030-2032; I. MIWA et al.: "Hypoglycemic activity of aldose reductase inhibitor, 1 (p-bromophenyl) sulfonyl hydantoin", whole article. *
CHEMICAL ABSTRACTS, Vol. 105, No. 11, 15th September 1986, page 337, Abstract No. 102604d, Columbus, Ohio, US; & JP,A,61 078 725 (AMERICAN HOME PRODUCTS CORP.) 22-04-1986, whole Abstract. *
Exp. Eye Res., Vol. 46, 1988, pages 517-530, Academic Press Ltd; M.F. LOU et al.: "Glutathione depletion in the lens of galactosemic and diabetic rats", whole article. *
Horm. Metab. Res., Vol. 10, 1978, pages 280-282, Georg Thieme Publishers; W. LIPPMANN et al.: "Effect of alrestatin on arginine-induced secretion of glycagon and insulin in the rat", Summary. *
Metabolism, Vol. 34, No. 10, October 1985, pages 885-892, Grune & Stratton, Inc.; N. SIMARD-DUQUESNE et al.: "The effects of a new aldose reductase inhibitor (Tolrestat) in galactosemic and diabetic rats", whole article. *
Metabolism, Vol. 34, No. 4, April 1985, pages 336-344, Grune & Stratton, Inc.; D. STRIBLING et al.: "Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat", Abstract. *
Metabolism, Vol. 35, No. 4, suppl. 1, April 1986, pages 83-92, Grune & Stratton, Inc.; J.B. JASPAN et al.: "Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes", Abstract. *
Metabolism, Vol. 36, No. 5, May 1987, pages 486-490, Grune & Stratton, Inc.; B. WALKER GRIFFIN et al.: "Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats", whole article. *
Pharmacology, Vol. 32, 1986, pages 52-60; A. BEYER-MEARS et al.: "Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor", Abstract. *
See also references of WO8806887A1 *

Also Published As

Publication number Publication date
JPH01503460A (en) 1989-11-22
KR890700346A (en) 1989-04-24
CA1310269C (en) 1992-11-17
WO1988006887A1 (en) 1988-09-22
AU1549088A (en) 1988-10-10
EP0306525A1 (en) 1989-03-15
AU598366B2 (en) 1990-06-21

Similar Documents

Publication Publication Date Title
AU3460989A (en) Improvements relating to surface plasmon resonance sensors
AU1892088A (en) Improvements in or relating to organic compounds
AU2490288A (en) Improvements in or relating to organic compounds
GB8807751D0 (en) Improvements in/relating to organic compounds
AU4815890A (en) Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
AU2417588A (en) Improvements in or relating to organic compounds
AU1889388A (en) Improvements in or relating to organic compounds
GB8810508D0 (en) Improvements in/relating to organic compounds
AU4292585A (en) Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
DE3573167D1 (en) Isotransferrins in body fluid sample as a measure of alcohol consumption
IL62847A (en) Pharmaceutical composition for the treatment of juvenile diabetes mellitus comprising insulin and l-carnitine and/or an l-acylcarnitine
GB8821429D0 (en) Improvements in/relating to organic compounds
AU1840988A (en) Improvements in or relating to organic compounds
HK168195A (en) Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
GB8803293D0 (en) Improvements in/relating to organic compounds
GB2211088B (en) Improvements relating to disposable vessels
EP0306525A4 (en) Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus
GB8801805D0 (en) Improvements in/relating to organic compounds
DK509289A (en) IMMOBILIZED FLUOROPHOR TO OXYGEN SENSOR
GB8807749D0 (en) Improvements in/relating to organic compounds
GB8800618D0 (en) Improvements in/relating to organic compounds
GB8816025D0 (en) Improvements in/relating to organic compounds
GB8810901D0 (en) Improvements in/relating to organic compounds
GB8816023D0 (en) Improvements in/relating to organic compounds
GB8804056D0 (en) Improvements in/relating to organic compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19890519

A4 Supplementary search report drawn up and despatched

Effective date: 19910306

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

DA4 Supplementary search report drawn up and despatched (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 19910805

17Q First examination report despatched

Effective date: 19920610

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930511